Clinical trials: Perimenopause
Postmenopausal Symptoms
Pharmacokinetic Evaluation of Brisdelle™ (Formerly Known as Mesafem) Following Single & Repeat Oral Administration in Healthy Postmenopausal Women
The purpose of this study is to assess the pharmacokinetics (absorption, breakdown and elimination from the body), safety and tolerability of Brisdelle (paroxetine mesylate) Capsules 7.5 mg when given as a single dose and…
- Trial name
- N30-005 (NCT01829919)
- Testing
- Brisdelle (paroxetine mesylate)
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Noven Therapeutics
Hot Flashes
24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms
To assess the safety and efficacy of Brisdelle (paroxetine mesylate) Capsules 7.5 mg for treatment of vasomotor symptoms (VMS) associated with menopause
- Trial name
- NCT01101841
- Testing
- Brisdelle (paroxetine mesylate)
- Where
- 32 sites in United States
- Volunteers
- 570 people
- Sponsor
- Noven Therapeutics
Perimenopausal Disorder, Stress, Emotional
The Menopause Transition: Estrogen Variability, Stress Reactivity and Mood
Women in the menopause transition ('perimenopause') are exposed to extreme hormone variability, tend to experience a unique set of severe stressors (e.g., divorce, death of loved ones), and are also at substantially elevated risk…
- Trial name
- Changes (NCT03003949)
- Testing
- Estradiol Patch, 0.1 Mg/24 Hours Weekly Transdermal Film, Extended Release, Progesterone Capsule
- Where
- 2 sites in United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Menopause, Hot Flashes
A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)
This study determined the effects of different doses and dosing regimens of ESN364 on the frequency and severity of hot flashes.
- Trial name
- NCT03192176
- Testing
- Fezolinetant
- Where
- 51 sites in United States
- Volunteers
- 356 people
- Sponsor
- Astellas Pharma Global Development, Inc.